Quantcast
Last updated on April 23, 2014 at 11:53 EDT

Latest Inositol Stories

2014-03-20 08:22:59

DUBLIN, March 20, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/vhdnv4/myoinositol_cas) has announced the addition of the "Myo-inositol (CAS 87-89-8) Market Research Report" [http://www.researchandmarkets.com/research/vhdnv4/myoinositol_cas ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Myo-inositol (CAS 87-89-8) Market Research Report presents comprehensive data on myo-inositol...

2014-02-28 08:25:07

-- All development and commercialization rights of ELND005 drug candidate have been transferred to an Irish-domiciled company ("Irish Subsidiary") -- Transition has acquired 100% of the common shares of Irish Subsidiary -- Irish Subsidiary will be responsible for the future development and commercialization of ELND005 for all disease indications -- Affiliates of Perrigo Company plc ("Perrigo") will...

2014-02-17 12:21:22

Vertellus is excited to announce its newest product NiaPro(TM) Encapsulated Niacin, an encapsulated feed-additive form of niacin. INDIANAPOLIS, Feb. 17, 2014 /PRNewswire/ -- NiaPro(TM)( )Encapsulated Niacin is formulated to control early digestion in the rumen and deliver an effective dose of niacin to the intestine, producing optimal benefits. The coating is durable but digestible and breaks down fully in the intestine. Niacin has been shown to benefit cows in lactation, especially...

2013-12-04 12:26:49

MAPLE GROVE, Minn., Dec. 4, 2013 /PRNewswire/ -- Dietary supplements are dominating the shelves of pharmacy retailers, with brands vying for the attention of health-conscious consumers. In fact, industry experts report that approximately 50% of American adults take dietary supplements. Despite the Dietary Supplement Health and Education Act (DSHEA) governing manufacturing, packaging and holding standards for the dietary supplement industry, it is difficult for consumers to be sure...

2013-12-02 12:23:06

DUBLIN, Ireland, December 2, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/qwkxgd/myoinositol_cas) has announced the addition of the "Myo-inositol (CAS 87-89-8) Market Research Report 2012" [http://www.researchandmarkets.com/research/qwkxgd/myoinositol_cas ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Myo-inositol (CAS 87-89-8) Market Research Report 2012...

2013-11-18 08:27:43

TORONTO, Nov. 18, 2013 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI) (TSX: TTH) announced ELND005 (scyllo-inositol) was featured in an oral and two poster presentations at the recently completed 6th Annual Clinical Trials in Alzheimer's Disease meeting that occurred November 13-16 in San Diego, CA. In addition, the conference included symposia that examined "Agitation and Aggression in AD: a new target for drug development" and "AD and...

2013-10-08 20:21:16

DUBLIN, October 8, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/jx29dl/dchiroinositol) has announced the addition of the "D-chiro-Inositol (CAS 643-12-9) Market Research Report 2013" [http://www.researchandmarkets.com/research/jx29dl/dchiroinositol ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) D-chiro-Inositol (CAS 643-12-9) Market Research Report 2013 presents comprehensive...

2013-09-04 12:32:25

MAPLE GROVE, Minn., Sept. 4, 2013 /PRNewswire/ -- September is National Cholesterol Education Month and leading cardiologist Dr. Carl Lavie, Medical Director of Cardiac Rehabilitation and Prevention at the John Ochsner Heart and Vascular Institute, New Orleans, LA, urges all Americans to know the basic facts about cholesterol management. A recent study from the Centers for Disease Control and Prevention reports that awareness about the importance of cholesterol management is on the...

2013-09-04 08:30:25

TORONTO, Sept. 4, 2013 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced the first patient dosing in a Phase 2a study of ELND005 in Down syndrome. Study ELND005-DS201 will evaluate the safety and pharmacokinetics of two doses of ELND005 and placebo in young adults with Down syndrome without dementia, and will also include select cognitive and behavioural measures. Information on the study design and protocol for...

2013-08-07 12:27:08

MAPLE GROVE, Minn., Aug. 7, 2013 /PRNewswire/ -- There has been a great deal of media coverage surrounding heart health and niacin, leaving some consumers confused about its benefits, according to leading cardiologist, Dr. Carl Lavie, Medical Director of Cardiac Rehabilitation and Prevention at the John Ochsner Heart and Vascular Institute, New Orleans, LA. For cholesterol-conscious consumers who are serious about optimizing heart health, Dr. Lavie stands by his long-term...